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Summary
Although growth hormone (GH) concentrations are not always pathologically elevated in patients with acromegaly, it has been suggested that the metabolic and somatic consequences of this condition may be due to a loss of the normal episodic secretion of G H . To examine the effects of maintaining modest but constant levels of circulating C H , we administered continuous subcutaneous infusions of growth hormone (CSIGEI) to eight previously untreated GH-deficient children (6-19 yr) .
CSlGH given for 90 h in doses equivalent to the standard dose for replacement therapy, raised mean serum GH levels from less than 3.0 to 5.9 + 1.0 ng/ml. In comparison, 24-h mean GH levels in five normal adolescents averaged 10.1 + 1.5 ng/ml. As expected, however, normals showed much more variability in G H concentration. The constant elevations in serum G H levels achieved with CSIGH produced significant impairment of oral glucose tolerance. During CSIGH, plasma glucose concentrations 60-1 20 min after oral glucose loading were 30-40 mg/dl higher than corresponding pre-infusion values (P < 0.01). This impairment of oral glucose tolerance during CSIGH occurred despite a doubling of the area under the insulin/time curve after oral glucose (P < 0.02 versus pre-infusion area). Indeed, plasma insulin lebels after oral glucose in patients on CSlGH exceeded those observed in normal controls, suggesting that CSIGH had induced a degree of insulin resistance.
There was a transient increase in plasma free fatty acid levels on the first day of CSIGH. Somatomedin-C concentration remained unchanged in four of six patients. We conclude that small but sustained increases in growth hormone concentrations in G H deficiency can, when infused continuously, have effects on fuel metabolism similar to those observed during pathologic G H hypersecretion.
Abbreviations CSIGH, continuous subcutaneous infusions of growth hormone FFA, free fatty acids C H , growth hormone GH-secreting pituitary adenomas are characterized clinically by excessive somatic growth and hyperinsulinemia with or without glucose intolerance. In a recent study of patients with such adenomas, however. Clemmons ' I a/. (3) demonstrated that the manifestations of acromegaly were not closely dependent on serum GH levels. Indeed, in certain individuals increased heel pad thickness and hyperglycemia were observed despite basal GH levels that lay within the normal range.
In healthy man. the secretion of G H is episodic with secretory bursts occurring mainly during sleep. Between bursts. serum G H often falls to undetectable levels (4). It is thus possible that some of the metabolic consequences of acromegaly might be attributable to the loss of the normal pulsatile pattern of G H release even in thc absence of marked elevations in serum G H concentrations.
T o test this hypothesis we examined the metabolic effects of sustained G H infusions. Previously untreated GH-deficient children were studied to eliminate the variability that could be introduced by endogenous G H secretion. The infusions produced sharp changes in glucose tolerance and an apparent resistance to insulin even though measured G H levels never exceeded 14 ng/ ml. These data support the view that metabolic derangements typical of those seen in acromegaly can be induced by sustained G H infusion even in the absence of marked elevations in serum G H concentrations.
PATIENTS AND METHODS
Eight childrcn and adolescents with G H deficiency and 12 normal controls participated in the study after written informed consent had been obtained. GH-deficient patients had presented with growth failure and. on evaluation of pituitary function, had subnormal G H responses to provocative stimuli including insulin hypoglycemia. Clinical details including primary diagnosis and concurrent medical therapy are given in Table 1 . None of the patients had been treated with G H before the start of the present study. and none received regular glucocorticoid replacement. Patients I and 7 had been treated with glucocorticoids during acute stress but had not received any such therapy for at least 3 mo before study. The study protocol was as follows:
Patients were admitted to the Yale Children's Clinical Research Center-on the day before study. At 0830 h on the following morning (after a 12-1 5 h overnight fast) a catheter was inserted into an antecubital vein for blood sampling. The patients rested in a recumbent position for 30 min before blood samples were obtained for determinations of FFA, somatomedin-C, and G H . Oral glucose (1.75 g/kg body weight to a maximum of 100 g) was then given and blood obtained every 30 min for 2 h for measurement of plasma glucose and insulin. The catheter was removed aftcr completioi of the oral glucose tolerance test.
On the evening of the same day (1700 h) a CSIGH was started using a small battery-powered infusion pump (Model AS-2C, Auto-Syringe, Inc.. Hooksett, NH). The pump was set to deliver 0. I I ml/h (given as 15 WL pulses every 8 min) and the concen- kg-'.dose-' three times weekly. G H was infused into the subcutaneous tissue of the anterior abdominal wall via a 27-gauge scalp vein needle, which was secured with tape. The injection site was inspected and changed daily. Apart from this brief interruption, the infusion was continued for a total of 90 h. Patients were fully ambulatory during the G H infusions and consumed a diet which, by detailed history, approximated their usual home intake. Each morning during the infusion blood was taken in the fasting state for measurement of FFA and G H levels. In addition, G H levels were measured daily in the late afternoon (between 1600 and 1800 h) during G h administration. On the morning of the fourth infusion day a second oral glucose tolerance test was carried out and fasting blood samples obtained just as on the first (pre-infusion) morning. G H infusion was discontinued after the completion of this second glucose tolerance test. Result:; of the oral glucose tolerance tests were compared with those of studies conducted in seven non-obese children and adolescents (ages, 7-13 yr) who had volunteered to act as normal controls. Five additional normal control children (ages. 11-15 yr) were admitted to the Children's Clinical Research Center for 24-h monitoring of G H levels. These subjects were studied under ambulatory conditions and blood was obtained every 2 h via. an indwelling catheter for measurement of G H levels.
Glucose was measured on a YSI Analyzer (Yellow Springs Instrument Company, Yellow Springs. OH) using a glucose oxidase technique. Insulin and G H (9). and somatomedin-C (Nichols Institute. San Pedro, CA) were measured by radioimmunoassay. The coefficient of variation of the plasma insulin assay is 8-1096. Plasma aminoacids were measured with an automated aminoacid analyzer (Beckman Instruments, Inc., I-ullerton. CA) after deproteination with sulfosalycilic acid. F' FA were measured by the method of Novak ct a/. (7) . Group data are presented as mean 2 SEM. Student's paired f test was used for the statistical analysis of the data.
RESULTS
CSlGH produced small but sustained elevations in G H concentrations (Fig. 1) . Mean plasma G H levels (less than 3 ng/ml, pre-treatment) increased to 5.9 L 1.0 ng/ml during the infusion. Even more importantly, in individual patients the coefficient of variation of fasting and random afternoon serum G H concentrations averaged only 2 1.3 2 2.3% during the infusion. Normal controls. on the other hand, showed slightly greater mean GH concentrations during 24-h monitoring (10.1 + 1.5 ng/ml). as well as much greater serum G H fluctuations. The coefficient of variation in individual normal subjects averaged 105 + 8% ( P < 0.00 1 rxrr.sza values in deficient patients during CSIGH).
As shown in Figure 2 , 9 0 h of CSIGH had no significant effect on fasting plasma glucose or insulin but sharply altered oral glucose tolerance. Plasma glucose values were 30-40 mg/dl above pre-infusion values from 60-120 min after oral glucose ( P < 0.01). Impaired glucose tolerance produced by G H infusion occurred in spite of an increase in circulating insulin concentrations. Plasma insulin levels during CSIGH were significantly elevated as compared with pre-treatment values beyond 60 min (PC 0.05). and the area under the insulin/time curve was alrnost doubled ( 10.2 2 4.3 vrrsils 5.7 2 1.6 m u . ml-I. min-I. P < 0.02). Figure 3 compares plasma glucose and insulin levels 120 min after glucose loading in the study patients before and after CSlIGH with corresponding values for normal controls. Before treatment, plasma glucose and insulin levels in deficient patients were similar to corresponding values in the normal subjects but they rose to values significantly higher than normal after 90 h of G H infusion.
ORAL GLUCOSE TOLERANCE PLASMA GLUCOSE AND INSULIN AT 120 MINUTES -* p < 0.005 ' 3 140 -I-V.S. NORMALS Fig. 3 . Plasma glucose and insulin levels 1 2 0 min after a standard oral glucose load in study subjects before and during continuous subcutaneo~~s glucose infusion of growth hormone (CSIGH) and in seven normal adolescent controls. Note that during growth hormone infusion both glucose and insulin were greater than in the controls. Fig. 4 . Somatomedin-C levels in seven of the patients, measured before and after 90 h of continuous subcutaneous growth hormone ~nfusion (CSIGH). 
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Glucose tolerance was impaired despite an exaggerated insulin
